{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The following hematology laboratory parameters were assessed: hemoglobin high, hemoglobin low, leukocytes high, leukocytes low, lymphocytes high, lymphocytes low, neutrophils low and platelets low. Laboratory abnormality events were graded according to NCI CTCAE v 4.03 (grade 1=mild, grade 2=moderate, grade 3= severe and grade 4= life-threatening). Participants with any hematology parameter meeting CTCAE grade 1 to 4 were reported.","groups":[{"description":"Participants received SEA-BCMA 1600 mg as an IV infusion q1wk as induction dose for the first two cycles, followed by q2wk as maintenance dose in subsequent cycles, of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part B: SEA-BCMA 1600mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA.","reportingStatus":"POSTED","timeFrame":"From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment up to 33 months (maximum follow up of 34 months)","title":"Number of Participants With Maximum Laboratory Toxicity Grade, by NCI-CTCAE v4.03- Hematology: Part B","type":"PRIMARY","unitOfMeasure":"Participants"}